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Abstract
Can we exploit our burgeoning understanding of molecular evolution to slow the progress of drug
resistance? One role of an infection clinician is exactly that: to foresee trajectories to resistance during
antibiotic treatment and to hinder that evolutionary course. But can this be done at a hospital-wide
scale? Clinicians and theoreticians tried to when they proposed two conflicting behavioural strategies
that are expected to curb resistance evolution in the clinic, these are known as ‘antibiotic cycling’ and
‘antibiotic mixing’. However, the accumulated data from clinical trials, now approaching 4 million patient
days of treatment, is too variable for cycling or mixing to be deemed successful. The former implements
the restriction and prioritisation of different antibiotics at different times in hospitals in a manner said to
‘cycle’ between them. In antibiotic mixing, appropriate antibiotics are allocated to patients but randomly.
Mixing results in no correlation, in time or across patients, in the drugs used for treatment which is why
theorists saw this as an optimal behavioural strategy. So while cycling and mixing were proposed as ways
of controlling evolution, we show there is good reason why clinical datasets cannot choose between them:
by re-examining the theoretical literature we show prior support for the theoretical optimality of mixing
was misplaced. Our analysis is consistent with a pattern emerging in data: neither cycling or mixing is
a priori better than the other at mitigating selection for antibiotic resistance in the clinic.
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Introduction
How best to use antibiotics is a question in
applied evolutionary biology of the most profound
importance for human health and yet it has
been called a ‘conceptually uninteresting’ scientific
problem for evolutionary biologists (Read and
Huijben, 2009). Concepts of how to best treat
with antibiotics remain as controversial as they
are important. For instance, the public is
told by medical professionals to adhere to the
fully prescribed course of antibiotics to prevent
resistance (Tabor, 2008) but this practise is also
said to ‘make no sense’ (Rice, 2008; Taubes, 2008)
based, as it is said to be, on an absence of data.
However, it is increasingly clear from molecular
studies of patient infections that clinical resistancec© The Author 2013. Published by Oxford University Press on behalf of the Soc ty for Molecular Biology a d Evolution. All right reserved.
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evolution occurs de novo (Blair et al., 2015;
Mwangi et al., 2007). There is, therefore, a
pressing need for molecular, evolutionary and
theoretical biologists to appropriate questions
posed by medics and to bring them from the
clinic into the laboratory, both wet and dry,
where the full gamut of investigative tools can be
brought to bear to provide the missing datasets
that will resolve debates such as this. We take
this approach with a question from evolutionary
medicine that has been posed many times before
where the answer is thought to be well understood.
We will show it is not. The question is this:
in an attempt to preserve their efficacy, should
hospitals, and intensive care specialists, mix or
cycle their antibiotics? It is now over thirty years
ago that clinicians asked whether a strategy of
antibiotic cycling might alleviate the resistance
problem (Gerding and Larson, 1985; McGowan Jr,
1986) and yet this remains an open problem.
Antibiotic cycling is the crop rotation idea
applied to antibiotics (Kollef et al., 1997).
Different antibiotics are prioritised against specific
infections for a period of time, only for that period
of drug prioritisation to be replaced by one of
restriction at a pre-determined later time, which
could be many months (Brown and Nathwani,
2005). It was hoped that cycling would select
against resistance alleles because one particular
drug would not be encountered by a pathogen
during a restriction cycle and so resistance would
‘reverse’ because of the fitness costs of being drug-
resistant (Kollef et al., 1997; Niederman, 1997).
Michael Niederman summarised this idea in a
question (Niederman, 1997): is the crop rotation
of antibiotics the solution to a resistance problem
in intensive care units? Later, predictions were
made using computer simulations of mathematical
models of different epidemiological scenarios
which claimed that cycling might reduce the
incidence of drug-resistant infection no better
than if we randomly allocated antibiotics to
patients (Bonhoeffer et al., 1997). The latter idea
has come to be known as ‘mixing’ because drugs
are mixed within the patient cohort; drugs are not
necessarily ‘mixed’ within patients. Treatments
which do that are called ‘combination therapies’
and these are used routinely in the clinic.
Comparing cycling against mixing provided a
useful observation about how to measure the
success of novel resistance mitigation strategies
as it provided an appropriate baseline measure.
But it was stated, later still, that cycling
different drugs must be suboptimal because a
strategy of maximal ‘heterogeneous antibiotic
use slows the spread of resistance’ (Bergstrom
et al., 2004). This idea taken literally, of
maximising the heterogeneity of drug prescription,
is now thought of as representing the de facto
theoretical optimum (Levin and Bonten, 2004).
And clinicians state as much (Sandiumenge et al.,
2006) in their work:
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“Mathematical models have shown that heterogeneous
antibiotic use, defined as a balanced use of the different
antimicrobials available, is the most likely way of
reducing the selection pressure that leads to antibiotic
resistance.”
and (Takesue et al., 2010)
“Heterogeneous antibiotic use has been suggested
[by mathematical models] to limit the emergence of
resistance.”
However, we contend that statements like these
are based on an over-generalisation of what the
details of the theory actually predict.
Results
Information is key in a toy model scenario
It is straightforward to see that antibiotic mixing
cannot be the theoretical optimum, at least not
in all theories. To understand why, imagine a
highly simplified, toy scenario whereby medics at
a clinic treat patients for infection by a particular
pathogen. To simplify matters completely so
this is a tractable model, we follow previous
mathematical modelling studies in assuming just
two drugs are available (Bergstrom et al., 2004;
Bonhoeffer et al., 1997), we also assume all
patients are infected and are treated. Previous
theories (Bergstrom et al., 2004; Bonhoeffer et al.,
1997; Levin and Bonten, 2004) do not name
the pathogen and nor do we. However, suppose
we are told that the pathogen exhibits reduced
susceptibility to ‘drug A’ in 90% of prior patient
cases but we do not have access to the diagnoses
capable of telling us which individual patients
these might be; again, nor do prior theories.
Suppose that the same pathogen exhibits reduced
susceptibility to the second drug ‘B’ to which
the pathogen exhibits resistance in only 10% of
prior cases. To simplify the situation even further,
we assume no AB cross resistance and no AB-
combination treatments are given.
Since we know nothing of individual patient
cases we are compelled to argue in terms of
‘patient fractions’ that receive one or other drug.
Now, if we give half the patients drug A and
the half other receive drug B, which is a mixing
strategy, the expected fraction of patients that
receive an appropriate treatment is this: (the
fraction treated with A)×(the fraction infected
by a pathogen susceptible to A) + (the fraction
treated with B)×(the fraction infected by a
pathogen susceptible to B) = 1
2
×(100−90)%+ 1
2
×
(100−10)%=50%. Suppose, on the other hand,
we give everyone drug B, which is not a mixing
strategy, then the expected fraction of patients
that receive an appropriate treatment is 0×(100−
90)%+1×(100−10)%=90%, a greater value than
the previous 50%. Thus the population is treated
appropriately more often, given the information
we have, if the drugs are not mixed within
the patient cohort. Furthermore, the worst thing
we can do is to give everyone drug A because
then only 1×(100−90)%+0×(100−10)%=10%
of patients are given the most appropriate drug.
And what of the resulting evolutionary
dynamics? This simple scenario says nothing
about how our strategy should change as
resistance evolves. So, to remedy this we make
the situation a little more general: suppose a
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fraction, a, of patients are given drug A, and
therefore the fraction 1−a receive drug B. Assume
an expected fraction, p, of patients have a drug-A
resistant infection and suppose q have a drug-
B resistant infection, where p 6=q. We now seek
a drug control strategy, a, that maximises the
likelihood of appropriateness of treatment.
The patient fraction treated with A that
exhibits a treatable, A-susceptible infection is
a·(1−p), the fraction treated with A but
with B-susceptibility is a·(1−q), the fraction
treated with B but with A-susceptibility is
(1−a) ·(1−p) and the fraction treated with B
exhibiting B-susceptibility is (1−a) ·(1−q). The
patient fraction treated with a drug that best
contributes to clearance of their infection is,
therefore, a(1−p)+(1−a)(1−q)=1−q+a(q−p).
This calculation is illustrated in Figure 1.
Antibiotic appropriateness is maximised when
1−q+a(q−p) is maximised over all possible
patient fractions, a, which is a number between 0
and 1. Since the quantity 1−q+a(q−p) depends
linearly on a, this means
a=
1 if q>p,0 if p>q. (1)
For the strategy defined in (1), max(1−p,1−q)
is the probability of appropriate treatment and
this value is as high as we can make it given
the information we have. We therefore call (1) an
optimal strategy.
As we this scenario knows nothing about
individual patients, according to (1) it is optimal
infected 
patient
1  p
1  q
A-resistant
A-susceptible
B-resistant
B-susceptible
drug
A
B1  a drug
fraction of appropriate treatmentchoose a so that this quantity is maximised.
infected 
atient
1  p
1  q
A-resistant
A-susceptible
B-resistant
B-susceptible
drug
A
B1  a drug
fraction of appropriate treatmentchoose a so that this quantity is maximised.
FIG. 1. An illustration of the toy scenario. A
patient seeks treatment and one of two antibiotics can
be administered. If the probability of resistant infection
to either drug, p and q respectively, can be estimated,
optimal behaviour maximises the likelihood of appropriate
therapy. This entails finding a that maximises 1−q+a(p−
q) where 0≤a≤1 but since this expression is linear in a, the
maximum occurs when a is zero or one. However, the worst
possible drug deployment protocol comes from minimising
this expression and this also arises when a is zero or one.
to treat everyone with the drug for which
resistance is least likely, even though this is a
population-wide strategy that will be sub-optimal
for some individuals. We can, therefore, improve
upon this solution by getting every individual
treatment decision right which means having
better information on individual circumstances,
from antibiograms for example, but this realistic
possibility is not part of our toy scenario.
We now seek the optimal strategy in the toy
scenario if the pathogens are allowed to evolve in
response to our behaviour as clinicians. Variables
p and q will change over time as a result and we
write p(t) and q(t) to allow this, t being time.
Analogous reasoning shows that the definition of a
in (1) should now be replaced by a time-dependent
4
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optimal strategy, a=aopt(t), where
aopt(t)=

1 if q(t)>p(t),
0 if p(t)>q(t),
give either drug if p(t)=q(t).
(2)
Observe how aopt(t) cycles ‘reactively’ between
drugs depending on which of p(t) or q(t) is
the greater. Note also how this strategy tacitly
requires that p(t) and q(t) can be estimated at all
times and that it leads to the most appropriate
treatment with probability 1
T
∫ T
0
max(1−p(t),1−
q(t))dt if the clinic is observed for a duration of T
time units.
The strategy aopt(t) has appeared before in
other theories: the importance of aopt(t) for
differential equation models of the antibiotic
deployment problem was demonstrated using
mathematical techniques from functional analysis
(Beardmore and Pena-Miller, 2010b). This idea
is also contained within a family of strategies
that was later termed ‘informed switching’ for
noisy differential equations (Kouyos et al., 2011).
Clinically, aopt(t) could be likened to surveillance-
based cycling where antibiotics are restricted
according to patterns in emerging drug resistance
data, an idea that has been trialled in the clinic
(Allegranzi et al., 2002; Gerding and Larson,
1985).
And what of mixing in this toy analysis?
A mixing protocol, amix(t), is a stochastically
fluctuating, knowledge-free strategy that can
fluctuate in time but whose ‘expected value’
(that we denote E) at all times is a number
between zero and one representing a constant,
unchanging bias towards one of the drugs: this
means E(amix(t))=β where β is that biasing
constant. If we are free to optimise the fraction
of appropriate treatments with respect to β
we can determine an ‘optimal mixing strategy’
that treats appropriately with probability 1
T
∫ T
0
1−
q(t)+β ·(q(t)−p(t))dt. But, for any fixed β, this
number is necessarily less than the optimal value
1
T
∫ T
0
max(1−p(t),1−q(t))dt we gave above for
aopt(t). So, our analysis shows, at least given the
assumptions in our toy scenario, it would be wrong
to mix drugs. For example, random mixing (a.k.a.
maximal drug heterogeneity) is the strategy that
sets β=1/2 which gives an appropriate treatment
in a mean fraction 1
T
∫ T
0
1
2
(1−q(t))+ 1
2
(1−p(t))dt
of cases, but this is also necessarily sub-optimal
relative to aopt(t).
This seems clearcut, but things get interesting
when we ask this: what is the worst strategy
possible? Can we determine that too? This is
the unfortunate case that gets the drug usage
decisions wrong with maximal probability. So A
(or B)-resistant infections are treated with drug
A (or B) as often as possible. This occurs when
we exchange a(t) with 1−a(t) in the optimal
strategy above, so the worst thing possible that
can be done in our toy scenario is to use the
cycling strategy abad(t) :=1−aopt(t) which gives
appropriate treatment to the fraction min(1−
p(t),1−q(t)) of patients at any given time.
It is unfortunate from a clinical perspective
5
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that the best and worst antibiotic management
protocols are cycling strategies, with mixing
sitting somewhere in between.
So, to summarise, our scenario manifests the
following ‘ordering property’ in terms of which
behavioural strategies select for resistance by
giving appropriate or inappropriate antibiotic
treatments: the best strategy available (aopt(t))
cycles drugs reactively through time and this
is preferable to the best mixing strategy. But
this, by definition, outperforms the worst mixing
strategy which outperforms the worst strategy
of all those we analysed, namely (abad(t)) which,
we repeat, is a reactive cycling strategy. Thus,
the best possible way of cycling performs better
than the mixing strategies which performs better,
in turn, than the worst cycling strategy. This
dichotomy with cycling and mixing is very hard
to escape (Beardmore and Pena-Miller, 2010b)
whichever modelling paradigm we analyse, as the
next section illustrates.
We first make a brief point concerning the term
‘optimal’. The strategy identified as optimal in
the above scenario may well not achieve what we
hope for. Dual resistance may well sweep through
the pathogen population, it may pass to fixation
and so render both our drugs impotent. It could
well be that the best we can achieve is simply to
slow this process because the long-term outcome
we would hope to engineer (namely, to prevent the
occurrence of resistance mutations) is not possible
once we begin to use the drugs. In other words,
‘theoretically optimal’ does not necessarily mean
‘desirable’ or clinically useful.
Moreover, strategies that are optimal for one
theoretical model need not be optimal for other
theoretical models, let alone have value in
the clinic. Indeed, it is only to be expected
that different optimality criteria, and different
modelling choices, will lead to different optimal
strategies even in the same mathematical model.
(As a technical aside, this issue is central to
condensed matter physics where free energy
is optimised and different optima correspond
to different states of matter.) Above we used
the criterion of maximising the likelihood of
appropriate treatment within a patient cohort
given that everyone is treated, but different
performance criteria might have asked us to
compromise on this. For example, if our criterion
had sought to maintain longevity of the drugs, the
optimal solution could well have drawn us into a
tradeoff of treating fewer infected patients (Foster
and Grundmann, 2006).
A second toy model
The above scenario could be criticised in many
different ways for a lack of realism, but do
its predictions generalise to more sophisticated
mathematical models? We address this question
by applying the theory of optimal control and
computational tools designed to solve dynamic
programming problems (Mitchell, 2008) to the
following differential equation model of antibiotic
6
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stewardship (Reluga, 2005):
d
dt
I1 = m1+I1(1−I1−I2)−γ1aI1, (3a)
d
dt
I2 = m2+I2(1−I1−I2)−γ2(1−a)I2. (3b)
Here a=a(t) is the patient fraction treated with
drug 1, 1−a(t) is the fraction of patients treated
with drug 2, I1 and I2 represent the densities
of patients infected with drug 2- and drug 1-
resistant strains, respectively, γ1 and γ2 are the
clearance rates of infection when patients receive
an appropriate antibiotic and m1 and m2 are
the admittance rates of patients to the clinic
infected by drug 2- and drug 1-resistant strains,
respectively. Finally I1(0) and I2(0) are assumed
known when t=0.
Only the case m1=m2 and γ1=γ2 is considered
in (Reluga, 2005) whereas we break this
symmetry, analogous to requiring that p 6=q in
the toy scenario, and consider other cases on the
grounds of realism. It is unlikely, for example, that
the rates of admittance of both patient classes I1
and I2 will be identical at all times. Moreover,
if a definitive ranking of mixing and cycling were
possible and clinically relevant, it would have to be
robust to all reasonable variations of parameters
in the model. We are therefore compelled to test
whether, or not, our conclusions are robust to
parameter changes in models like (3).
Now, the optimal control problem for (3)
asks us to find a function a(t) so that the
totality of infected patient days
∫ T
0
I1+I2 dt is
minimised, where T >0 is some fixed observation
time. Control theory tells us that the optimal
strategy can be determined by solving the so-
called Hamilton-Jacobi-Bellman (HJB) equation
associated with (3) numerically. This numerical
approach determines optimal controls as so-
called ‘feedback laws’ whereby a=φ(t,I1,I2) for
some function φ (see (Mitchell, 2008) and
Supplementary Text for details).
Supplement figs. 1 illustrates that when
m1=m2 and γ1=γ2, the optimal control law
approximates the function we determined for the
toy scenario:
a=
1 if I1>I2,0 if I1<I2. (4)
However, when m1 6=m2 or γ1 6=γ2, Supplement
figs. 1 shows the optimal law can resemble the
asymmetric control law
a=
1 if I1>θ ·I2,0 if I1<θ ·I2. (5)
where θ depends on system parameters.
It must be noted that the strategies (1) and
(4) do not preclude the optimality of antibiotic
mixing, although this point is mathematically
technical. This is because there could be
theoretical cases where I1(t)≈I2(t) most of the
time along optimal solution trajectories, in which
case a near-optimal reactive control a would
oscillate very rapidly between the deployment of
either drug. While this phenomenon known as
‘chattering’ would be irrelevant to the clinic, it
could arise in theory if a mixing solution, whereby
a=1/2, were either very close to being optimal or
7
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else were optimal. However, as we discuss in the
supplementary, this requires mathematical models
to possess special symmetry properties.
A third model of antibiotic use
Although very simple, equation (3) broaches the
limits of what can be gleaned using mathematical,
analytic tools. So, in order to progress, we now
present two other models based on assumptions
that have been articulated elsewhere (Bergstrom
et al., 2004; Bonhoeffer et al., 1997) for which
we cannot determine optimal antibiotic controls
but that we can use to compare mixing and
cycling. We will present synthetic data from both
models in order to illustrate the generality of our
arguments.
The first of these models, equation (6), assumes
two antibiotics are available to treat infected
patients, labelled 1 and 2. It assumes S is the
proportion of patients in the hospital infected
by a drug-susceptible pathogen, that R1 then
represents the proportion of patients infected by
a drug-1-resistant pathogen, similarly for R2, and
then X is the proportion of uncolonised patients.
The model is this:
d
dt
S = µ(m−S)−(τ1+τ2+γ)S+βSX+...
...+σβ(c1R1+c2R2)S, (6a)
d
dt
R1 = µ(m1−R1)−(τ2+γ)R1+β(1−c1)R1X−...
...−σβ(c1S+(c1−c2)R2)R1, (6b)
d
dt
R2 = µ(m2−R2)−(τ1+γ)R2+β(1−c2)R2X−...
...−σβ(c2S+(c2−c1)R1)R2, (6c)
d
dt
X = µ(1−m−m1−m2−X)+(τ1+τ2+γ)S+...
...+(τ2+γ)R1+(τ1+γ)R2−...
...−βX(S+(1−c1)R1+(1−c2)R2). (6d)
Equation (6) contains parameters
(µ, σ, m, m1, m2, γ, β, α, τmax, c1 and c2)
the meanings of which are stated in Table 1.
Note that (6) makes no explicit reference to
mechanisms of drug resistance evolution, whether
de novo mutation in the chromosome of the
pathogen or else through horizontal gene transfer.
Both do occur in the clinic and, we believe, are
likely to require different mitigation strategies.
Now, in (6), τ1 and τ2 represent rates of use
of drugs 1 and 2, where all patients are assumed
treated with one of the drugs. This results in a
constraint, τ1+τ2=τ , where τ a fixed constant
that plays the role of ‘a’ in our previous discussion.
Following (Bergstrom et al., 2004) we seek a
function, τ1(t), which minimises the total fraction
of patient days observed with a drug-resistant
infection,
∫ T
0
R1+R2dt, where T denotes a fixed
observation time. This, again, is a question in
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Table 1. The meaning of the parameters in equation (6).
description parameters
Patients enter hospital in states S,R1 and R2 at rates µm,µm1 and µm2 respectively m,m1,m2
Rate of use of drugs 1 and 2 per unit time (days) τ1,τ2
Fitness cost of resistance to pathogens c1,c2
Relative rate of secondary colonization to primary colonization σ
Rate constant for colonization of uncolonized individuals β
Rate of patient turnover in the hospital µ
Represents physician compliance with cycling program α
Untreated patients colonized by susceptible bacteria remain colonized 1/γ days on average γ
optimal control but not one that can be easily
solved. So, in the absence of any better strategies,
we will apply the reactive cycling solution (4) to
(6) and ask how it performs in relation to mixing.
Before doing this, we first generalise (6) so
that the antibiotic usage protocol, τ1(t), can be
explicitly stochastic. This is done by introducing
a random process into (6) so that τ1(t) represents a
noisy, time-varying deployment protocol such that
E(τ1(t))=α(t) for each t≥0, where E(·) denotes
expectation (see Supplementary Text) and α(t) is
some defined protocol that we expect clinicians
to adhere to; α(t) could, for example, represent a
mixing or a cycling protocol.
The second model we refer to is (7) below
from (Bonhoeffer et al., 1997, Case III). It
uses a slightly different terminological convention
with ‘A’ and ‘B’ for the drug labels and x=
(x,yw,ya,yb). In this model x is the density of
patients uninfected by a pathogen, yw represents
the number of patients infected by a wild-type
pathogen strain, ya denotes the number of patients
with a drug-A resistant strain, similarly for drug-B
resistant yb:
dx
dt
= λ−dx−b(yw+ya+yb)x+rwyw+raya (7a)
... +rbyb+h(1−s)((fa+fb)yw+fayb+fbya),
dyw
dt
= (bx−c−rw−h(fa+fb))yw, (7b)
dya
dt
= (bx−c−ra−hfb)ya+hsfayw, (7c)
dyb
dt
= (bx−c−rb−hfa)yb+hsfbyw, (7d)
where the epidemiological parameters are
(λ, d, c, h, rw, s, ra, rb,b) whose interpretation
is stated in Table 2. There are no multidrug-
resistant strains in (7) and although that case has
been considered in (Bonhoeffer et al., 1997), for
brevity we do not discuss it.
Here fa and fb represent the fraction of the
population treated with drugs A and B and
assuming everyone is treated, meaning fa+fb=
1, following (Bonhoeffer et al., 1997) we seek a
function fa(t) so that the total of all patient
infected-days, i.e.
∫ T
0
yw+ya+yb dt,
is minimised.
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Table 2. The meaning of the parameters in equation (7).
description parameters
the fraction of patients treated with antibiotic A and B fa,fb
recovery rates of wild-type, A-res and B-res infected hosts rw,ra,rb
transmission rate of infection b
maximum rate at which patients are treated h
fraction of patients that acquire resistance when treated s
per capita death rate of uninfected hosts d
arrival rate of uninfected hosts λ
infected hosts’ death rate c
The reactive control strategies are, in the case
of (6),
τ1(t)=τ ·a(t), τ2(t)=τ ·(1−a(t))
and, in the case of (7),
fa(t)=a(t), fb(t)=1−a(t).
Typical solutions that equation (7) produces when
supplemented with this reactive control strategy
are shown in Figure 2 (bottom panel, see label ‘1’.
The data for (6) are similar but are not shown
for reasons of brevity.) To produce Figure 2 we
implemented
a(t)=
1 if ya(t)<yb(t)0 if ya(t)>yb(t) (8)
in (7) and this figure compares numerical solutions
of the reactive cycling strategy (8) with those of
the optimal mixing protocol determined for (7).
They show, by example, that reactive cycling can
outperform optimal mixing.
However, Figure 2 gives just one comparison
of optimal mixing and reactive cycling. To probe
whether this comparison is representative of the
general case we used a stochastic version of
(7) to determine ‘performance histograms’. To
determine performance histograms we computed
the performance, namely the total number of
infected patient days for a given model (i.e.
with fixed parameters) for both reactive cycling
and optimal mixing strategies using 107 different
numerical realisations of stochastic versions of (6)
and (7). Figure 2 (top panel, see orange histogram
and label ‘2’) then shows the resulting histograms.
Note how reactive cycling outperforms optimal
mixing in almost all the simulations of the
particular model realisation that we tested. (We
determined performance histograms for all cycling
and mixing strategies in a comparable manner, see
the supplementary for details).
Implications of synthetic data in Figure 2 for
clinical trials
There is an important difference between the
reactive cycling strategies, and cycling, used in
theory and cycling in the clinic. Although some
clinical studies have utilised ideas that might be
described as reactive cycling (Allegranzi et al.,
2002; Brown and Nathwani, 2005; Gerding and
Larson, 1985; Takesue et al., 2006, 2010), we
know of no clinical studies that implement reactive
cycling in exactly the way (8) defines it. Rather,
clinical trials make use of scheduled cycling
protocols based on fixed periods of drug rotation
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FIG. 2. (top panel) Two performance histograms (orange
and yellow, respectively) illustrate that reactive cycling can
outperform all the scheduled cycling protocols. (bottom
panel) Two timeseries from the stochastic version of (7)
using (1, left) a protocol that cycles reactively between
antibiotics and (2, right) optimal mixing: protocol (1)
outperforms optimal mixing (2) as can be seen in the top
panel. Variables in the legend of (2) are defined in equation
(7) and performance here is the number of observed infected
patients days.
(Brown and Nathwani, 2005; Hedrick et al., 2008;
Martinez et al., 2006; Raymond et al., 2001).
So, to create a fair comparison, we must also
compare (8) with the scheduled drug rotations
that implement fixed, periodic cycles of antibiotic
prioritisation and restriction, and we must then
compare this with antibiotic mixing.
Moreover, clinical cycles of antibiotic
prioritisation and restriction vary considerably
in duration, from one month (P. Toltzis M. J.
Dul C. Hoyen A. Salvator M. Walsh L. Zetts,
2002), to three (Hedrick et al., 2008; Smith et al.,
2008; Warren et al., 2004) to six (Kollef et al.,
1997). Indeed, many clinical cycling studies have
been criticised on the basis of not implementing
repeated periods of cycling (Brown and Nathwani,
2005). Issues like these are difficult to avoid in
practice but they are not relevant to theoretical
studies where we can perform exhaustive searches
using mathematical and computational models.
So, when we simulated theoretical cycling
strategies based on scheduled drug rotation of
fixed cycling periods, we obtained a second
performance histogram, part of which can be seen
in Figure 2 (top panel, yellow histogram). This
histogram shows the performance of entire families
of cycling protocols based on a sampling of many
different scheduled rotations (see supplementary).
Importantly, Figure 2 (top panel) shows that
while reactive cycling outperforms scheduled
rotation, many scheduled cycles outperform
optimal mixing. It also appears as if the
performance histogram of the family of scheduled
cycling strategies contains the performance of
optimal mixing right in its midst. It transpires
this feature is no quirk because mathematical
antibiotic deployment models, like equations (6)
and (7), are compelled to have this property. For
details of the argument supporting this outcome,
see (Beardmore and Pena-Miller, 2010a) and the
supplementary.
Let us explain this feature more carefully. When
differential equation models are used to examine
11
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FIG. 3. The structure of performance histograms of all
cycling and all mixing protocols for a typical theoretical
model. The shaded regions, each with unit area, illustrate
that the range of performances of the cycling protocols
is at least as wide as that of the mixing protocols and
a series of numerical examples in the text illustrates this
for specific models. Note that the ‘optimal cycling’ and
‘optimal mixing’ performance can coincide in this figure
whereupon the blue and yellow histograms would have
identical ranges. Note also, when illustrating this figure
using mathematical model simulations in the text, we do
not plot the performance histogram for all the mixing
protocols, rather just optimal mixing (coloured green),
worst mixing (red) and random mixing (blue) are indicated.
the question of optimal antibiotic deployment,
the two families of clinical strategies known as
cycling (meaning scheduled rotation) and mixing
(maximal antibiotic heterogeneity) must exhibit
comparable levels of drug resistance in the sense
that their performance distributions can always be
embedded into each other, with complete overlap
of their performance ranges (Beardmore and
Pena-Miller, 2010a). This statement is illustrated
as a schematic in Figure 3. It follows from this that
for each mathematical model and each suboptimal
antibiotic mixing protocol in it, there is a protocol
which cycles antibiotics and which performs better
than that mixing protocol. However, there is also
another antibiotic cycling protocol with a different
cadence of drug cycles which performs worse
than mixing. Moreover, even if optimal mixing
outperforms most cycling protocols, there are still
some cycling protocols that perform nearly as well,
infinitesimally close, in fact, to the performance
of optimal mixing (Beardmore and Pena-Miller,
2010a). So, if we were to ask which is better in
general, cycling or mixing a priori, given this, it
seems hard to say.
FIG. 4. Top and bottom panels show two sets of
performance histograms for (6) for cycling (107 simulations
in total) and three mixing protocols (10,000 simulations
each). Consistent with Figure 3, both panels exhibit
complete overlap in performances as indicated by the
horizontal bars. While both use simulation data from
equation (6), the top panel has different costs of resistance
from the bottom panel that uses ‘symmetric’ parameter
values that bias in favour of random mixing. In the latter, as
the bottom panel shows, there is a low probability of finding
a cycling protocol that can approach the performance
of random mixing, although some do. Note, this figure
does not show the performance histogram for all mixing
protocols in the manner done in Figure 3, rather histograms
determined from stochastic simulations of (6) are shown for
optimal mixing (green), the worst possible mixing (red) and
random mixing (blue). Here (bottom) the blue and green
histograms coincide so only the green one is visible.
All these arguments can be summarised by a
single schematic, which is Figure 3. Figure 3
is derived from theoretical arguments but it is
clinically relevant and it says this: if one were
to randomly select just one antibiotic mixing
protocol and one cycling protocol and implement
both within the same mathematical model, as
if one were making a clinical trial comparison
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where very few such comparisons are possible,
one could not be a priori certain (i.e. before the
models are simulated) which strategy will select
most against resistance a posteriori. In a clinical
context, where a limited number of trial conditions
can be tested, in practise just a handful with no
chance of determining performance histograms,
which cycling cadence or mixing strategy should
we choose? This decision is critical to ultimate
performance of that trial but there is no way of
knowing how to optimise this choice a priori, just
as there is no way of doing so in a mathematical
model comparing mixing and cycling.
So why did prior theoretical studies (Bergstrom
et al., 2004; Bonhoeffer et al., 1997; Levin and
Bonten, 2004) conclude that antibiotic mixing
was optimal, both in theory and for the clinic?
First, those studies only showed that mixing could
outperform cycling in exemplar simulations, this
does not show mixing is an optimal strategy,
although it does show that cycling is not. Another
potential answer is an unintentional bias: prior
studies biased the way parameter sets were chosen
with an outcome that is illustrated in Figure 4
(bottom).
To explain Figure 4 suppose, for sake of
argument, that a mathematical model contains
‘rate of recovery when treated’ parameters, ρ1
and ρ2 for either drug, say, but suppose that
ρ1=ρ2 is assumed. Numerical assumption like
this were used in prior studies because an
argument can be made that such assumptions
engender a parsimonious, like-for-like comparison
between two antibiotics with identical clinical
effects whereby the only point of difference
imposed in that model is that one cycles the
drugs and another mixes them. This argument
does seem appropriate to the question we are
addressing, but it also leads to mathematical
symmetries (Beardmore and Pena-Miller, 2010b)
that produce a systemic bias, as illustrated Figure
4, that is not representative of optimal antibiotic
deployment solutions in the general case. This
kind of symmetry was already an issue in the toy
scenario above whereby we needed a particular
inequality, p 6=q, in order to avoid a triviality in
that discussion.
Please note that Figure 4, and the remaining
figures, do not show the performance histogram
for all mixing protocols in the manner done in
Figure 3, rather they just show histograms for
optimal mixing (coloured green throughout), the
worst possible mixing (in red) and random mixing
(in blue) using 104 stochastic model simulations.
Performance histograms for mixing protocols are
depicted alongside horizontal bars that illustrate
the numerical range of 104 stochastic simulations
for that mixing protocol, where all simulations
are performed with the same noise parameter (see
supplementary).
While Figure 3 is merely a schematic showing
cycling and mixing are impossible to separate
in terms of their overall performance, the
structure of this figure is readily observed in
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specific mathematical models when we compute
performance histograms, as Figure 4 illustrates.
Figure 4 also shows that while Figure 3 is
representative of model outcomes irrespective of
particular parameter choices, those choices can
happen to skew in favour of random mixing, and
against cycling, if parameters are chosen to have
the symmetries we mention above. For instance, if
we impose a symmetry of the form m1=m2,r1=r2
and c1=c2 in (6) we can skew our computations in
favour of mixing. The mathematics behind these
symmetries are discussed in detail in (Beardmore
and Pena-Miller, 2010b).
Figure 4 (top) shows a second realisation of
equation (6) that uses different numerical values
for the parameters defined in Table 1. This
figure still highlights how the overlapping nature
of the performance distributions of mixing and
scheduled cycling is present, just as it should be
according to Figure 3. However, the choice of
parameter values when mixing was said to be
optimal (Bergstrom et al., 2004) are symmetric
and have skewed the performance distribution
(Figure 4 (bottom)). This choice ensures highly-
performing cycling strategies are rare and cycles
that are highly performing exchange the drugs
unfeasibly quickly.
To further illustrate that our conclusions,
as embodied in Figure 3, are not model-
specific, we present Figure 5 determined using
equation (7). Consistent with Figure 3, the
performance histograms of mixing and cycling
FIG. 5. (top) This illustrates Figure 3 using performance
histograms determined from equation (7), although only
three mixing histograms are shown (random, optimal and
worst). The range of performances, from the best to worst
mixings, and the range of the cyclings are shown as
horizontal bars: note how they overlap consistent with
Figure 3. (bottom) The random mixing protocol (indicated
with a 2 in top and bottom panels) is deployed into a
stochastic version of (7) and it outperforms one cycling
protocol (label 3) but it under performs another cycling
(label 1). This ordering property is a general feature of
theoretical models like (7).
(i.e. scheduled rotation) protocols are embedded
within each other. For equation (7) the definition
of performance is different, there it is the total
number of infected patient days (Bonhoeffer et al.,
1997), and yet the properties of the ranges of the
performance distributions of mixing and cycling
are just as before, they overlap.
Discussion
Despite the problems, theory is useful when
contrasting antibiotic mixing and cycling. The
manifold decisions made when designing a clinical
trial are almost impossible to standardise, but
one can standardise mathematical models. This is
important. For example, suppose the drug order
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of cefepime, ciprofloxacin, piperacillin-tazobactam
and imipenem-cilastatin in the quarterly cycles
described to tackle drug-resistant Pseudomonas
aeruginosa in (Hedrick et al., 2008) had been
different? Suppose the trial had instead restricted
ciprofloxacin entirely and implemented twice-
yearly cycles? What then? The possibilities are
almost limitless. How could one even hope to
implement the various empirical controls needed
to understand how such changes would impact
on resistance evolution in the clinic? This lack
of standardisation is seen by clinicians as a
driver behind some of the problems in answering
Niederman’s question (Brown and Nathwani,
2005). However, we have shown that determining
a priori which of cycling and mixing selects
best against drug resistant pathogens is still not
possible, even when we carefully standardise the
questions using mathematical models.
Intriguingly, deterministic and stochastic
models of the antibiotic deployment problem have
been said to have different optimal strategies:
deterministic models have mixing strategies,
stochastic models have switching strategies
(Kouyos et al., 2011). As our derivations of
treatments that outperform mixing apply equally,
whether or not the models are stochastic, there
is no such dichotomy here and the theoretical
reasons supporting the existence of such a
dichotomy are not clear. Instead, here, we find
the key theoretical issue is how much clinical
and microbiological information each resistance
mitigation strategy is able to exploit.
A tacit expectation in this field of study is a,
quite reasonable, hope that the construction of
theoretical epidemiological models will definitively
resolve questions on how we should act in the
clinic to prevent antibiotic resistance evolution.
But why should this be so? If the expectation
of modellers had been that we might identify
circumstances in which, say, Figure 6 were
possible, whereby mixing is definitively optimal,
then, unfortunately, this is not the case
(Beardmore and Pena-Miller, 2010a, b) at least
not when using ‘SI models’ commonly applied
in mathematical epidemiology. And equations (6)
and (7) are SI models.
all cyclingsall mixings
worst!
mixing
performance
fr
eq
ue
nc
y optimal!
cycling
FIG. 6. A schematic of impossible performance histograms.
If this outcome were possible in a theoretical model, we
would then be certain that mixing antibiotics outperforms
cycling in a mathematical model, but it has been
shown (Beardmore and Pena-Miller, 2010a, b) that this
arrangement of histograms cannot arise in equations of the
form (6) and (7).
Ultimately, the technical, mathematical reason
(Beardmore and Pena-Miller, 2010b) for the
impossibility of Figure 6 is this: constant functions
(aka mixing) controls can be approximated by
oscillatory functions (aka cycling) as closely
as we like in ‘weak topologies’ of spaces of
antibiotic control functions. When the equations
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of SI models, and their performance criteria,
define continuous mappings with respect to those
topologies Figure 6 cannot apply. Thus, even if
mixing were optimal in such a model, we could
do just as well by cycling drugs quickly and
this forms the main idea for the mathematical
proof (Beardmore and Pena-Miller, 2010a) behind
Figure 3. Whether this has any relevance to the
clinic depends on what the term ‘quickly’ means
in practise. Indeed, one can cycle drugs every day
in a model, one cannot do that in the clinic.
So, mathematic models tell us that some of
the difficulties of comparing mixing and cycling
are inherent to the theory behind Niederman’s
question. They cannot be resolved, not even
within the solution sets of certain mathematical
models, be they deterministic or stochastic. We
should not, therefore, be surprised when clinical
trials designed to rank cycling and mixing also
prove inconclusive. After all, clinical trials cannot
even begin to resolve performance distributions.
This uncertainty likely contributes to the ongoing
community debates as to the relative merits
of cycling and mixing (see http://goo.gl/
Ztywjg). Meanwhile, trials continue, like the
recent multinational study, the Saturn Project,
that is said to be designed to ‘resolve an
issue of high controversy (antibiotic cycling vs.
mixing)’ (see http://www.saturn-project.eu),
whose authors recently stated this about their
data:
‘...there were no statistically significant differences in
the prevalence of antibiotic resistance during mixing
and cycling interventions.’
We propose that Figure 3 might provide a
theoretical explanation of this statement.
Like cycling, mixing has been tested in at least
three prior clinical studies (Ginn et al., 2012;
Takesue et al., 2006, 2010). It did contribute to
a reduction in resistant Gram-negative infections
in a hospital-wide study (Takesue et al., 2010)
but fared less well when implemented in an
intensive care unit (Takesue et al., 2006). It
was partially successful in one study where
it may have contributed to a reduction in
MRSA infection, but without impacting on
Gram-negative infections (Schultsz et al., 2013).
However, such positive outcomes might equally
be attributed to pathogen-specific measures as to
mixing, such as the reduction of carbapenem usage
correlating with reduced carbapenem resistance in
Pseudomonas aeruginosa (Takesue et al., 2010)
or the introduction of infection control measures
known to be effective in limiting fomite-spreading
pathogens like MRSA (Schultsz et al., 2013).
Indeed, a recent clinical study concluded (Ginn
et al., 2012) that ‘...prescribing homogeneity per
se does not appear to be a specific resistance
driver.’ One analysis of over 3.5M patient-days
of antibiotic use data across 42 hospitals ‘found
no significant relationship between [antibiotic]
diversity and the proportion of resistant pathogens’
(Pakyz et al., 2008).
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It is not straightforward to find consistency in
the available clinical data (Brown and Nathwani,
2005; John Jr, 2000; McGowan Jr, 1986) and, in
summary, there is data both for (Sandiumenge
et al., 2006; Takesue et al., 2010) and against
mixing (Takesue et al., 2006) but the same can be
said of cycling. The support for cycling (John Jr,
2000; Martinez et al., 2006; Raymond et al., 2001)
is tempered by others who advocate against it,
or who at least indicate their indifference to it
(P. Toltzis M. J. Dul C. Hoyen A. Salvator M.
Walsh L. Zetts, 2002; van Loon et al., 2005;
Warren et al., 2004). To give one more example,
the cycling of linezolid and vancomycin in an
ICU was called a ‘promising method to reduce
infections with MRSA’ (Smith et al., 2008) but
cycling was also implicated as the cause of an
outbreak of multi-drug resistant Pseudomonas
aeruginosa (Hedrick et al., 2008).
Cycling clearly cannot work if resistance to
antibiotics is not lost after a drug is withdrawn
(Enne et al., 2001) or if it returns to baseline
levels soon after drugs are reinstated (Brown and
Nathwani, 2005). In all this variation, a concensus
has emerged describing the body of trial data
as ‘inconclusive’ (Kouyos et al., 2011). From our
analysis of the theory, and given Figure 3, this
variation is not surprising.
An individual-based treatment model
As a de´nouement, we sought a way of bringing
the individual patient into this discussion. It is
individuals that we treat with antibiotics and
yet, to our knowledge, no theoretical treatment
of mixing deals with individuals. Patient-specific
evolution occurs during treatment (Blair et al.,
2015; Mwangi et al., 2007) and this may mean
that individualised treatments (pathogen-specific
and host-specific) will be necessary to properly
optimise antibiotic use. Indeed, the FDA has
approved devices that can target infections based
on a rapid diagnosis of the pathogen from
molecular signatures or blood cultures (Bergeron
and Ouellette, 1998a, b; Jung et al., 2014; Sullivan
et al., 2013), including devices for Clostridium
difficile (Ber, 2008). We predict that if these
approaches are considered within mathematical
studies, mixing will not be the optimal way
of using antibiotics there either because the
principle that better decisions accrue from better
information (Beardmore and Pena-Miller, 2010b)
will apply.
To test this, we implemented an agent-based
computational model (see supplementary) in
which a much-simplified hospital ward contains an
array of ‘beds’ and a randomly ordered ‘queue’
of patients is treated until all have recovered
(Figure 7). When admitted to the ward, patients
are infected with a community-acquired pathogen
that shares an ecological niche and engages in
competition with a commensal bacterium within
the host. We do not name the pathogen, it is
merely a simulation of a bacterium in a framework
for comparing resistance mitigation strategies
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FIG. 7. Illustrating the individual-based model. (a)
This shows ‘health state dynamics’ of a patient during a
sequential antibiotic treatment: blue and green coloured
areas show the drug used and the subsequent load
of drug-resistant and drug-susceptible pathogens in the
host through time. The black line is the density of a
commensal bacterium that competes with the pathogen
for resources. The patients is deemed ‘recovered’ when
the commensals have outcompeted the pathogen. (b) This
shows treatments in a ward of five beds where a queue of
seven patients (labelled {1,2,3,4,5,6,7}) is to be treated.
Coloured boxes indicate the protocol where green and blue
boxes, respectively, denote patients only treated with one of
the two available drugs, a red outline denotes the discharge
of a recovered patient and the arrival of a new patient. (c)
An illustration of the spatial structure in the ward resulting
from one realisation of the model using a queue of twenty
patients and five beds where a seven-day cycling protocol
has been implemented, blue and green colours represent
different drugs used. The relative frequency of each of
the two single-drug resistant pathogens in each patient is
shown in the right-most skyscraper illustrating that drug
resistance is correlated with the drug usage policy. Grey
regions are hosts carrying equal fractions of two different
single-drug resistant pathogens, blue and green colours
indicate that one of the drug resistant strains dominates
the infection of the host in that bed.
where the unit of treatment are individuals rather
than population classes.
The pathogen causes illness but it is not life
threatening and the commensal will eventually
outcompete the pathogen (Figure 7(a)). However,
the rate of patient recovery can be increased by
treating appropriately with one of two antibiotics
and patients are discharged when their infection
is deemed to have reached an ‘asymptomatic’
density threshold. A patient from the queue is
then assigned to the newly-freed bed and treated.
Different protocols are ranked using the mean
length of stay (LoS) statistic for each queue
where shorter LoS statistics represent better
performance.
Different treatment strategies in the clinic
and the individual-based model
We implemented several antibiotic stewardship
protocols in this model following the many
strategies implemented in practise: cycling
(Hedrick et al., 2008; Martinez et al., 2006;
Raymond et al., 2001); mixing based on the
adjustment of future prescription patterns by
monitoring prior prescription data (Sandiumenge
et al., 2006; Takesue et al., 2006, 2010);
surveillance-based cycling (Allegranzi et al.,
2002; Gerding and Larson, 1985); rapid DNA-
based diagnoses with an appropriate drug then
given (Bergeron and Ouellette, 1998a, b); patient-
by-patient rotation of antibiotics (Sandiumenge
et al., 2006) and, finally, the de-escalation of a
combination therapy (Ame, 2005; Smith et al.,
2008). For a review of other clinical protocols, we
refer to (MacDougall and Polk, 2005).
A ‘reactive mixing’ protocol that turns
prior infection data into future stewardship
practise has also been evaluated in the clinic:
the PAMS methodology (‘periodic antibacterial
monitoring and supervision’) maximises antibiotic
heterogeneity because drugs used in the past
gain a low probability of being used in the
future (Takesue et al., 2006). A numerical
index, essentially information entropy, measures
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antibiotic heterogeneity and prescription
maximises this index as time progresses. PAMS
does not account for patterns of resistance that
emerge during a trial, but it is hoped it will
respond to patterns of drug use that might
correlate with resistance.
Based on this survey, the following protocols
were simulated in the individual-based model:
(1.) random sequential treatment: each patient
receives a random drug each day (extreme
mixing that maximises drug heterogeneity);
(2.) empirical treatment: a random drug is
allocated to the patient but not changed
thereafter (also mixing);
(3.) scheduled rotation (periodic cycling): cycles
of prioritisation and restriction are fixed
before any patients are admitted;
(4.) periodic antibiotic monitoring and
supervision (PAMS): the next patient
admitted is treated with the antibiotic that
maximises the heterogeneity of drugs used
so far (mixing);
(5.) surveillance-based rotation: the drug
estimated to have the lowest current
prevalence of resistance from recent
antibiograms is prescribed to all patients
(the strategy from the toy scenario);
(6.) Personalised (DNA-based) treatments: a
rapid assessment is made of the genotype
responsible for infection for every patient.
Reassessments conducted during treatment
yield a sequential monotherapy that
maximises drug appropriateness at all
times, even if resistance emerges in the host
during treatment.
We do include multidrug resistance in this
model but we do not implement combination
therapy as it is not clear how to engineer a fair,
like-for-like comparison of the performance of drug
combinations in a theoretical test of mixing and
cycling.
Individual-based model outcomes
In the absence of treatment, the length of
stay (LoS) data are normally distributed whereas
they are log-normally distributed when everyone
is treated using empirical therapy (Figure 8).
Interestingly, empirical treatment reduces the
mean LoS relative to treating no-one, but it
also increases the LoS variance (Figure 8). So,
although most patients fare better when treated,
empirical treatment exhibits the following tragedy
of the commons (Foster and Grundmann, 2006):
as resistance spreads, some patients fare worse
when everyone is treated empirically than if
nobody had been treated. Empirical treatment of
course works well if it allocates the correct drug,
which happens by chance in 50% of cases, but the
LoS data increases when an inappropriate drug is
administered, also in 50% of cases (Figure 8(b-d)).
This is why treating empirically has such a large
variance in its LoS data.
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Figure 9 shows this model is consistent with the
idea that there is a sweet spot LoS with respect to
antibiotic cycling cadence, so that cycling works
best when neither too fast nor too slow. However,
determining the optimal cycling cadence so we can
profit from this observation would be unfeasible
in practise. Also note how the LoS at the sweet
spot in Figure 9 performs in relation to other
strategies in Figure 10: an LoS of about 7 days
means optimal cycling can perform just as well
as any protocol. However, other cycling strategies
also perform poorly, as bad as having a LoS of two
weeks when the drugs are cycled too slowly.
FIG. 8. Individual model LoS statistics with no
treatment and empirical treatment. (a) The mean
length-of-stay distribution (LoS) when no patient is treated
with antibiotics is a normal distribution with mean
close to 16 days for the parameter values implemented
(see supplementary). (b) The LoS distribution when
treating empirically follows a log-normal distribution in
the same conditions. (c) We grouped patients treated with
empirical therapy into two a posteriori classes: appropriate
and inappropriate, according to the drug administered.
Accordingly, the LoS distribution when drug use is
inappropriate in empirical therapies have both higher mean
and variance. Inappropriate drug allocation is therefore
responsible for the large variance of the empirical treatment
strategy in (b). (d) For illustrative purposes: a Kaplan-
Meier plot illustrating the LoS for the two classes from
(c).
Figure 10 summarises our final main result:
one cannot rank strategies 1-6 outlined above
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FIG. 9. The optimal cycling period for this one particular
instance of the individual patient model is very short at
about 3 days. That it is so small relative to real-world
clinical trials is likely due to the rapid turnover of patients
in the model and the fact that there is no evolution of
resistance among pathogens in the community that supplies
patients to the model.
definitively because their LoS distributions
overlap. Other outcomes are possible in differently
parameterised instances of this model, but the
set of simulations shown in Figure 10 indicates
the patient-specific treatment (strategy 6) can
sometimes produce the lowest mean LoS. Delays
in using DNA tests to determine the pathogen
can decrease performance. For instance, if, during
the delay, empirical therapy is given, a delay of
two days decreases drug appropriateness to 80%
(see Figure 11(a), this model outcome is consistent
with values observed in the clinic (Shorr et al.,
2008)) and LoS performance deteriorates towards
that of empirical therapy as the delay increases
further (Figure 11(b)). Finally, surveillance-based
rotation (that according to the toy scenario should
approximate optimal cycling) and PAMS (a
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reactive form of mixing) have similar performance
in this model (Figure 10).
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FIG. 10. We can improve upon mixing and cycling
cadences by rapidly diagnosing the pathogen
genotype responsible for infection. LoS distributions
for different strategies show the optimal treatment exploits
most of the available information (the rapid, DNA-
based, diagnosis strategy). Empirical treatment, using no
information at all, is the worst performing strategy here,
although it is preferable to cycling with very long cycling
times (see Figure 9).
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FIG. 11. Delaying the availability of pathogen
genotype information leads to deterioration in
performance of the patient-specific treatment. (a)
Delaying the availability of pathogen drug-susceptibility
information decreases drug appropriateness to about 80%
of patients with a two-day delay and to no better than
random (i.e. empirical treatment) with very long delays.
(b) Consistent with this, long delays increase the expected
LoS and give this protocol performances close to empirical
treatment (shown are LoS means ± 95% CI from 1000
model simulations).
We conclude that information-rich, personalised
protocols can outperform antibiotic cycling and
mixing in some mathematical models but, we
should emphasise, this conclusion will depend on
nuanced model circumstances. For example, if all
patients are infected with pathogens susceptible
to both drugs, a personalised strategy will not
outperform mixing because any treatment will
be successful. At the other extreme in terms of
the community prevalence of resistance, if multi-
drug resistance has fixed in the pathogen in the
community and so is present in all infections
before patients begin their treatment, it will
also matter little which treatment patients are
given because none will work. However, before
that stark situation arises, and somewhere in
between these two extremes, our simulation data
shows that targeting appropriate treatments at as
many individuals as possible can outperform both
mixing and cycling.
Supplementary Material
Supplementary Text is available at
Molecular Biology and Evolution online
(http://www.mbe.oxfordjournals.org/).
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